Journal ArticleDOI
Anti-cancer drugs
Reads0
Chats0
About:
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.read more
Citations
More filters
Journal ArticleDOI
The status of platinum anticancer drugs in the clinic and in clinical trials.
TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI
Natural products to drugs: natural product derived compounds in clinical trials
Mark S. Butler,Mark S. Butler +1 more
TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Cellular distribution and functions of P2 receptor subtypes in different systems.
TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI
Natural products: an evolving role in future drug discovery.
Bhuwan B. Mishra,Vinod K. Tiwari +1 more
TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.
References
More filters
Journal ArticleDOI
Repeated intake of broccoli does not lead to higher plasma levels of sulforaphane in human volunteers.
TL;DR: The plasma pharmacokinetic characteristics of the chemopreventive isothiocyanate sulforaphane were determined in six human volunteers following single and repeated intake of raw broccoli and there was no evidence of accumulation.
Journal ArticleDOI
Soluplus-Solubilized Citrated Camptothecin—A Potential Drug Delivery Strategy in Colon Cancer
TL;DR: Cytotoxicity studies conducted with the formulation of solid dispersion with citric acid, utilizing cell cytotoxicity test (MTT test) on Caco-2 cells, confirmed cytotoxic nature of the formulation.
Journal ArticleDOI
A Selective Account of Effective Paradigms and Significant Outcomes in the Discovery of Inspirational Marine Natural Products
TL;DR: This account reviews some of the major advances in the study of marine biomolecules made at UC Santa Cruz over more than three decades and touches on prospects for future outcomes involving new sources and strategies.
Journal ArticleDOI
Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Liping Zhang,Hong Zhang,Yining Zhao,Zhe Li,Shangke Chen,Jing Zhai,Yunyun Chen,Wei Xie,Zhong Wang,Qing Li,Xuehua Zheng,Xiaopeng Hu +11 more
TL;DR: Crystal structures reported here reveal a surprising Trp112 native conformation stabilized by a specific Gln114‐centered hydrogen bond network in the AKR1B10 holoenzyme, and suggest that AKR 1B1 inhibitors could retain their binding affinities toward AKR2B10 by inducing Trp 112 flip to result in an “AKR1 B1‐like” active site in AKR3B10.
Journal ArticleDOI
Triple-negative breast cancer: novel therapies and new directions.
TL;DR: In this article, a review of targeted strategies for triple negative breast cancer (TNBC) is presented, where the focus is directed towards novel targeted strategies, such as poly(ADP-ribosyl)ation polymerase (PARP) inhibitors BSI-201 and olaparib.